ANI Pharmaceuticals, Inc. (ANIP) has reported a significant increase in revenue expectations for 2026, raising its guidance by $25 million to a total net revenue outlook of $1.08-$1.14 billion. In 2025, the company generated $347.8 million from Cortrophin Gel, a product that is becoming central to its growth strategy, with projections for 2026 set between $540-$575 million.
In Q1 2026, ANI Pharmaceuticals recorded a revenue of $237.5 million, surpassing expectations by over 15%, and adjusted earnings per share reached $2.05, exceeding the $1.28 consensus estimate by nearly 60%. The company utilized a strategy involving generics and product launches to enhance this outlook. However, it faces risks from increased competition in the retinal market and customer concentration, as three wholesale customers accounted for 53% of 2025 net revenue.
As of March 31, 2026, ANI reported $311.2 million in cash and $625 million in debt, indicating manageable leverage that supports ongoing investments. The company plans to initiate a $100 million share repurchase program, reinforcing confidence in its financial trajectory amid market challenges.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
